Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
The DOI matches its Crossref record; 281 of the 281 references it cites were found in a registry or an index.
Abstract
Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters. Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small molecules. This Review discusses the role of altered expression and/or function of one class of epigenetic regulators--histone deacetylases (HDACs)--and their role in cancer, neurological diseases and immune disorders. We highlight the development of small-molecule HDAC inhibitors and their use in the laboratory, in preclinical models and in the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is increasing evidence that KDAC inhibitors work best in combination with other therapies [28–30]”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [29]
In the citing paper
“Growing evidence supports that epigenetic dysregulation through histone deacetylases (HDACs) plays a critical role in synaptic dysfunction and memory loss in Alzheimer’s disease”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDACs are epigenetic modulators that deacetylate lysine residues in histone and nonhistone substrates and their inhibition has attracted much interest for the treatment of neurodegenerative disorders, as several isoforms seem to be implicated in AD memory-related dysfunction: HDAC2 is a nuclear isoform that reduce transcription of CREB-regulated genes involved in learning and memory, HDAC6 targets”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [118]
Citations
Cites
4 retracted
Zhang, X., Zhao, X., Fiskus, W., Lin, J., Lwin, T., Rao, R., Zhang, Y., Chan, J. C., Fu, K., Marquez, V. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.003 · Cited by 276
RetractedChen, C.-S., Wang, Y.-C., Yang, H.-C., Huang, P.-H., Kulp, S. K., Yang, C.-C., Lu, Y.-S., Matsuyama, S., Chen, C.-Y., & Chen, C.-S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3996 · Cited by 187
RetractedDasmahapatra, G. P., Lembersky, D., Kramer, L. B., Fisher, R. I., Friedberg, J. W., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 115
RetractedDasmahapatra, G. P., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 62
RetractedChromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 3×
“AML1 and the AML1–ETO fusion protein in the pathogenesis of t(8;21) AML.”
BackgroundLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Cited by
Items 301–400 of 1,003
Trivedi, P., Adhikari, N., Amin, S. A., Jha, T., & Ghosh, B. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.08.030 · Cited by 66
“These could help to design the selective HDAC inhibitors (Salisbury and Cravatt, 2007; Falkenberg and Johnstone, 2014).”
BackgroundLian, B., Chen, X., & Shen, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1164514 · Cited by 75
“Expert Opin Investig Drugs (2017) 26 (8):965–71.”
BackgroundAriffin, J. K., Gupta, K. D., Kapétanovic, R., Iyer, A., Reid, R. C., Fairlie, D. P., & Sweet, M. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01876-15 · Cited by 64
Guo, S., Zhu, Q., Jiang, T., Wang, R., Shen, Y., Zhu, X. M., Wang, Y., Bai, F., Ding, Q., Zhou, X., et al. (2016) · Modern Rheumatology · doi:10.1080/14397595.2016.1218595 · Cited by 67
Zhang, C., Zhang, E., Yang, L., Tu, W., Lin, J., Yuan, C., Bunpetch, V., Chen, X., & Ouyang, H. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.043 · Cited by 65
Sabbatini, M., Zanellato, I., Ravera, M., Gabano, E., Perin, E., Rangone, B., & Osella, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01860 · Cited by 63
RetractedJang, Y.-G., Ko, E., & Choi, K. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108444 · Cited by 66
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Luo, Y., & Li, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228828 · Cited by 62
“In neurological diseases, HDACis can induce neuroprotection and the expression of neurotrophins [8,27].”
BackgroundInfluentialTargeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors
Zhang, Y., Rong, D., Li, B., & Wang, Y. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02055 · Cited by 63
Yuan, Z., Sun, Q., Li, D., Miao, S., Chen, S., Song, L., Gao, C., Chen, Y., Tan, C., & Jiang, Y. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.017 · Cited by 62
Controlling Plasma Stability of Hydroxamic Acids: A MedChem Toolbox
Hermant, P., Bosc, D., Piveteau, C., Gealageas, R., Lam, B., Ronco, C., Roignant, M., Tolojanahary, H., Jean, L., Renard, P., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01444 · Cited by 64
Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery
Chen, W., Dong, G., Wu, Y., Zhang, W., Miao, C., & Sheng, C. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00414 · Cited by 62
Cognitive epigenetic priming: leveraging histone acetylation for memory amelioration
Burns, A. M., & Gräff, J. (2021) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2020.08.011 · Cited by 62
“Non-histone targets of HDACis Although the range of action of HATs and HDACs are mostly associated with histone acetylation, these enzymes can also substantially modify non-histone proteins [38].”
HDAC1 inhibition ameliorates TDP-43-induced cell death in vitro and in vivo
Sanna, S., Esposito, S., Masala, A., Sini, P., Nieddu, G., Galioto, M., Fais, M., Iaccarino, C., Cestra, G., & Crosio, C. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2580-3 · Cited by 64
Noonepalle, S. K. R., Shen, S., Ptáček, J., Tavares, M. T., Zhang, G., Stránský, J., Pavlíček, J., Ferreira, G. M., Hadley, M. M., Pelaez, G. D., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00567 · Cited by 64
Design, synthesis and evaluate of novel dual FGFR1 and HDAC inhibitors bearing an indazole scaffold
Liu, J., Qian, C., Zhu, Y., Cai, J., He, Y., Li, J., Wang, T., Zhu, H., Li, Z., Li, W., et al. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.12.041 · Cited by 63
Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer
Giannopoulou, A. F., Velentzas, A. D., Konstantakou, E. G., Avgeris, M., Katarachia, S. A., Papandreou, N. C., Kalavros, N., Mpakou, V., Iconomidou, V. A., Anastasiadou, E., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061291 · Cited by 65
“HDACis are generally classified by their chemical structure, target selectivity/specificity and inhibitory concentrations which range from nM (nano-molar) to mM (milli-molar) scales [134,186,187].”
BackgroundRegulating Methylation at H3K27: A Trick or Treat for Cancer Cell Plasticity
Das, P., & Taube, J. H. (2020) · Cancers · doi:10.3390/cancers12102792 · Cited by 65
“Epigenetic information, marked in histone structures, is decoded by these reader proteins, which can bind to chromatin marks using specific structures, such as chromodomains and PHD domains [249].”
BackgroundHistone deacetylases and their inhibitors in inflammatory diseases
Zhang, S.-Y., Zhang, L., Wen, R., Yang, N., & Zhang, T. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117295 · Cited by 89
Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies
Matthews, G. M., Mehdipour, P., Cluse, L. A., Falkenberg, K. J., Wang, E., Roth, M., Santoro, F., Vidacs, E., Stanley, K., House, C. M., et al. (2015) · Blood · doi:10.1182/blood-2015-03-632984 · Cited by 59
Self-citationZhijun, H., Shusheng, W., Min, H., Jianping, L., Li-Sen, Q., & Li, D. (2016) · Tumor Biology · doi:10.1007/s13277-016-4868-6 · Cited by 60
Histone deacetylase inhibitors in multiple myeloma: from bench to bedside
Harada, T., Hideshima, T., & Anderson, K. C. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2008-0 · Cited by 65
A T cell-specific deletion of HDAC1 protects against experimental autoimmune encephalomyelitis
Göschl, L., Preglej, T., Hamminger, P., Bonelli, M. M., Andersen, L., Boucheron, N., Gülich, A. F., Müller, L., Saferding, V., Mufazalov, I. A., et al. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.09.008 · Cited by 62
Proteolysis targeting chimeras (PROTACs) for epigenetics research
Vogelmann, A., Robaa, D., Sippl, W., & Jung, M. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.01.010 · Cited by 58
Non-Histone Arginine Methylation by Protein Arginine Methyltransferases
Al-Hamashi, A. A., Diaz, K., & Huang, R. (2020) · Current Protein and Peptide Science · doi:10.2174/1389203721666200507091952 · Cited by 62
Vaidya, G. N., Rana, P., Venkatesh, A., Chatterjee, D. R., Contractor, D., Satpute, D. P., Nagpure, M., Jain, A. K., & Kumar, D. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112844 · Cited by 60
Role of histone modifications in neurogenesis and neurodegenerative disease development
Zhao, A., Xu, W., Han, R., Wei, J., Qi, Y., Wang, M., Li, H., Li, M., & Chi, G. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102324 · Cited by 71
Galdeano, C., & Ciulli, A. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0059 · Cited by 59
Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators
Zhan, P., Itoh, Y., Suzuki, T., & Liu, X. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00229 · Cited by 60
Ciarlo, E., Heinonen, T., Théroude, C., Herderschee, J., Mombelli, M., Lugrin, J., Pfefferlé, M., Tyrrell, B. E., Lensch, S., Acha‐Orbea, H., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01037 · Cited by 64
“In addition, HDACs target thousands of non-histone proteins affecting many biological processes (3).”
Yuan, Z., Chen, S., Gao, C., Dai, Q., Zhang, C., Sun, Q., Lin, J., Guo, C., Chen, Y., & Jiang, Y. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.03.027 · Cited by 60
The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs
Geurs, S., Clarisse, D., De Bosscher, K., & D’hooghe, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00226 · Cited by 58
Histone deacetylases as therapeutic targets — From cancer to cardiac disease
Abend, A., & Kehat, I. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.003 · Cited by 63
Harnessing the cyclization strategy for new drug discovery
Tang, K., Wang, S., Gao, W., Song, Y., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.022 · Cited by 64
The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy
Moran, B., Davern, M., Reynolds, J. V., Donlon, N. E., & Lysaght, J. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216121 · Cited by 64
Pinkerneil, M., Hoffmann, M. J., Kohlhof, H., Schulz, W. A., & Niegisch, G. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0444-7 · Cited by 63
BRD4 inhibition for the treatment of pathological organ fibrosis
Stratton, M. S., Haldar, S. M., & McKinsey, T. A. (2017) · F1000Research · doi:10.12688/f1000research.11339.1 · Cited by 58
“…by the fact that four histone deacetylase (HDAC) inhibitors are FDA-approved for the treat-ment of cancer 41,42 , that HDAC inhibitors have also shown promise in treating non-oncologic diseases such as Duchenne muscular dystrophy 43 , and that HDAC inhibitors are fairly well tolerated in humans 1 .”
BackgroundRole of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis
Citraro, R., Leo, A., Santoro, M., D’Agostino, G., Constanti, A., & Russo, E. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612823666171024130001 · Cited by 60
“Hydroxamates comprise the largest class of HDACI that act as pan-HDACIs and show low selectivity [23, 84].”
Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy
Magno, L. D., Coni, S., Marcotullio, L. D., & Canettieri, G. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.06.003 · Cited by 61
The epigenetics of tumour initiation: cancer stem cells and their chromatin
Avgustinova, A., & Benitah, S. A. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.01.003 · Cited by 58
Ramaiah, M. J., Naushad, S. M., Ponnusamy, L., Arivazhagan, G., Sakthiprasad, V., & Pal‐Bhadra, M. (2017) · Gene · doi:10.1016/j.gene.2017.10.018 · Cited by 61
Hammond, N., Munkacsi, A. B., & Sturley, S. L. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.04.002 · Cited by 59
Mohamed, M. F. A., Youssif, B. G. M., Shaykoon, M. S. A., Abdelrahman, M. H., Elsadek, B., Aboraia, A. S., & Abuo‐Rahma, G. E. A. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103127 · Cited by 57
Krieger, V., Hamacher, A., Cao, F., Stenzel, K., Gertzen, C. G. W., Schäker‐Hübner, L., Kurz, T., Gohlke, H., Dekker, F. J., Kassack, M. U., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01489 · Cited by 59
Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes
Chen, J., Li, Y., Zhang, J., Zhang, M., Wei, A., Liu, H., Xie, Z., Ren, W., Duan, W., Zhang, Z., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112868 · Cited by 56
Management of myelodysplastic syndromes after failure of response to hypomethylating agents
Pérez, Á. G., & Bravo, G. M. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719847059 · Cited by 55
Osko, J. D., & Christianson, D. W. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127023 · Cited by 56
Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases
Irwin, M. H., Moos, W. H., Faller, D. V., Steliou, K., & Pinkert, C. A. (2016) · Drug Development Research · doi:10.1002/ddr.21294 · Cited by 59
Mirza, A., Fry, M. A., Urman, N. M., Atwood, S. X., Roffey, J., Ott, G. R., Chen, B., Lee, A. G., Brown, A. S., Aasi, S. Z., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.97071 · Cited by 56
“HDAC inhibitors block growth and promote apoptosis by altering the histone-DNA complex and by altering the acetylation status of nonhistone proteins (12).”
BackgroundGalow, A.-M., & Peleg, S. (2022) · Cells · doi:10.3390/cells11030468 · Cited by 64
Pu, J., Liu, T., Wang, X., Sharma, A., Schmidt‐Wolf, I. G. H., Jiang, L., & Hou, J. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00507-5 · Cited by 68
“HDACs have a crucial function in controlling gene expression by altering the acetylation state of histones, which are proteins involved in the packaging and organization of DNA in the cell nucleus [28, 29].”
BackgroundTao, J. Z., Li, J., Fan, X., Jiang, C. Q., Wang, Y., Qin, M., Nikfard, F., Nikfard, F., Wang, Y., Zhao, T., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102489 · Cited by 63
Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma
Pritchard, E. M., Dyer, M. A., & Guy, R. K. (2016) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666150722100610 · Cited by 59
Epigenetic-based therapy: From single- to multi-target approaches
Benedetti, R., Conte, M., Iside, C., & Altucci, L. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.10.016 · Cited by 58
Histone deacetylase 6 negatively regulates NLRP3 inflammasome activation
Hwang, I., Lee, E., Jeon, S., & Yu, J. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.10.033 · Cited by 55
Paradoxical roles of dual oxidases in cancer biology
Little, A. C., Sulovari, A., Danyal, K., Heppner, D. E., Seward, D. J., & van der Vliet, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.05.024 · Cited by 56
Duan, Y., Jin, L., Ren, H.-M., Zhang, S., Liu, Y.-J., Xu, Y., He, Z., Song, Y., Yuan, H., Chen, S.-H., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113453 · Cited by 57
Zhao, P., Qiu, J., Pan, C., Tang, Y., Chen, M., Song, H., Yang, J., & Hao, X. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154810 · Cited by 57
Epigenetic regulation of cancer stemness
Galassi, C., Manic, G., Esteller, M., Galluzzi, L., & Vitale, I. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02340-6 · Cited by 69
“13,14 However, a number of questions remain to be answered to unlock the full therapeutic potential of CSC-targeted epigenetic drugs.”
Hsu, K., Liu, C., Lin, T. E., Hsieh, J.-H., Sung, T.-Y., Tseng, H.-J., Yang, J., & Huang, W. (2017) · Scientific Reports · doi:10.1038/s41598-017-03417-1 · Cited by 60
Chen, J., Li, D., Li, W., Yin, J., Zhang, Y., Yuan, Z., Gao, C., Liu, F., & Jiang, Y. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.06.016 · Cited by 54
He, X., Hu, X., Zhu, C., Zhou, K., Zhao, W.-J., Zhang, C., Han, X., Wu, C.-L., Wei, Y.-Y., Wang, W., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01740-5 · Cited by 54
“ous T cell lymphoma following the Food and Drug Administration approval [50].”
Exercise and the Skeletal Muscle Epigenome
McGee, S. L., & Walder, K. R. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029876 · Cited by 60
Small-Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy
Xiao, W., Zhou, Q., Wen, X., Wang, R., Liu, R., Wang, T., Shi, J., Hu, Y., & Hou, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.702360 · Cited by 51
Differential Anti-inflammatory Activity of HDAC Inhibitors in Human Macrophages and Rat Arthritis
Lohman, R., Iyer, A., Fairlie, T., Cotterell, A. J., Gupta, P. K., Reid, R. C., Vesey, D. A., Sweet, M. J., & Fairlie, D. P. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.229328 · Cited by 55
Insights into Lysine Deacetylation of Natively Folded Substrate Proteins by Sirtuins
Knyphausen, P., de Boor, S., Kuhlmann, N., Scislowski, L., Extra, A., Baldus, L., Schacherl, M., Baumann, U., Neundorf, I., & Lammers, M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.726307 · Cited by 56
Control and Eradication Strategies of Hepatitis B Virus
Shih, C., Chou, S.-F., Yang, C.-C., Huang, J., Choijilsuren, G., & Jhou, R. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.05.006 · Cited by 56
Mohammadi, A., Sharifi, A., Pourpaknia, R., Haftcheshmeh, S. M., & Sahebkar, A. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.05.009 · Cited by 56
Stabilization of Protein–Protein Interactions in chemical biology and drug discovery
Bier, D., Thiel, P., Briels, J. M., & Ottmann, C. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2015.05.002 · Cited by 59
Stahl, M. F., Gore, S. D., Vey, N., & Prébet, T. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1146251 · Cited by 55
Recruitment of the Mammalian Histone-modifying EMSY Complex to Target Genes Is Regulated by ZNF131
Varier, R. A., Pau, E. C. D. S., van der Groep, P., Lindeboom, R. G. H., Matarese, F., Mensinga, A., Smits, A. H., Edupuganti, R. R., Baltissen, M. P. A., Jansen, P. W. T. C., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.701227 · Cited by 57
Pace, M. J., Williams, J., Kurioka, A., Gerry, A. B., Jakobsen, B. K., Klenerman, P., Nwokolo, N. C., Fox, J., Fidler, S. J., Frater, J., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005782 · Cited by 54
Gene expression profiling in the human alcoholic brain
Warden, A. S., & Mayfield, R. D. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.02.017 · Cited by 59
Yu, W., Lü, W., Chen, G., Cheng, F., Su, H., Chen, Y., Liu, M., & Pang, X. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13961 · Cited by 54
“They target tumour cell proliferation, cell cycle, apoptosis, senescence, cell migration and angiogenesis (Abend and Kehat, 2015; Falkenberg and Johnstone, 2014).”
BackgroundBernhart, E. M., Stuendl, N., Kaltenegger, H., Windpassinger, C., Donohue, N., Leithner, A., & Lohberger, B. (2017) · Oncotarget · doi:10.18632/oncotarget.20460 · Cited by 58
Yuan, Y., Peng, Q., & Gurunathan, S. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s136142 · Cited by 53
Retractedvon Tresckow, B., Sayehli, C. M., Aulitzky, W. E., Goebeler, M.-E., Schwab, M. G., Braz, E., Krauss, B., Krauss, R., Hermann, F., Bartz, R., et al. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13188 · Cited by 57
Regulatory T cell heterogeneity and therapy in autoimmune diseases
Zhang, R., Miao, J., & Zhu, P. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102715 · Cited by 54
Nührenberg, T. G., Hammann, N., Schnick, T., Preißl, S., Witten, A., Stoll, M., Gilsbach, R., Neumann, F., & Hein, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131019 · Cited by 53
Rational design and diversity-oriented synthesis of peptoid-based selective HDAC6 inhibitors
Diedrich, D., Hamacher, A., Gertzen, C. G. W., Avelar, L. A. A., Reiß, G. J., Kurz, T., Gohlke, H., Kassack, M. U., & Hansen, F. K. (2016) · Chemical Communications · doi:10.1039/c5cc10301k · Cited by 53
Park, H., Garrido‐Laguna, I., Naing, A., Fu, S., Falchook, G. S., Piha-Paul, S. A., Wheler, J. J., Hong, D. S., Tsimberidou, A. M., Subbiah, V., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11750 · Cited by 51
Chen, J., Zheng, Y., Xu, C., Gu, L.-Z., Ding, Z., Qin, L., Wang, Y., Fu, R., Wan, Y.-F., & Hu, C. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0307 · Cited by 51
“In addition, Class II HDACs have also suggested to mediate the effect of VPA (Falkenberg and Johnstone, 2014), although results suggested that class II HDACs may be significantly less aJian-Hui Chen, Yu-Long Zheng, Chuan-Qin Xu and Li-Zhi Gu: These authors contributed equally to this work.”
BackgroundInfluentialThe enzyme activity of histone deacetylase 8 is modulated by a redox-switch
Jänsch, N., Meyners, C., Muth, M., Kopranovic, A., Witt, O., Oehme, I., & Meyer‐Almes, F. (2018) · Redox Biology · doi:10.1016/j.redox.2018.09.013 · Cited by 51
Ojha, R., Nepali, K., Chen, C., Chuang, K.-H., Wu, T.-Y., Lin, T. E., Hsu, K., Chao, M., Lai, M.-J., Lin, M.-H., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112086 · Cited by 52
Steimbach, R. R., Herbst‐Gervasoni, C. J., Lechner, S., Stewart, T. M., Klinke, G., Ridinger, J., Géraldy, M. N. E., Tihanyi, G., Foley, J. R., Uhrig, U., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c05030 · Cited by 51
Proteomic characterization of post-translational modifications in drug discovery
Zhai, L., Chen, K., Hao, B., & Tan, M. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-01017-y · Cited by 59
“To date, five HDAC inhibitors, predominantly pan-HDAC inhibitors, have been approved for clinical use in cutaneous T-cell lymphoma (CTCL) and MM, including vorinostat, romidepsin, belinostat, panobinostat, and tucidinostat [75].”
BackgroundEpigenetic changes as a common trigger of muscle weakness in congenital myopathies
Rokach, O., Sekulic‐Jablanovic, M., Voermans, N. C., Wilmshurst, J. M., Pillay, K., Heytens, L., Zhou, H., Muntoni, F., Gautel, M., Nevo, Y., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv195 · Cited by 56
Drugging Chromatin in Cancer: Recent Advances and Novel Approaches
Cai, S. F., Chen, C.-W. D., & Armstrong, S. A. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.042 · Cited by 58
Conde, E., Rivilla, I., Larumbe, A., & Cossío, F. P. (2015) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5b01418 · Cited by 50
Oya, Y., Mondal, A., Rawangkan, A., Umsumarng, S., Iida, K., Watanabe, T., Kanno, M., Suzuki, K., Li, Z., Kagechika, H., et al. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.12.015 · Cited by 51
Stenzel, K., Hamacher, A., Hansen, F. K., Gertzen, C. G. W., Senger, J., Marquardt, V., Marek, L., Marek, M., Romier, C., Remke, M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01538 · Cited by 51
Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways
Lernoux, M., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.004 · Cited by 55
Triazol: A Privileged Scaffold for Proteolysis Targeting Chimeras
Xia, L., Ba, M.-Y., Liu, W., Cheng, W., Hu, C.-P., Zhao, Q., Yao, Y., Sun, M., & Duan, Y. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0159 · Cited by 52
Mangiatordi, G. F., Intranuovo, F., Delre, P., Abatematteo, F. S., Abate, C., Niso, M., Creanza, T. M., Ancona, N., Stefanachi, A., & Contino, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01357 · Cited by 52
Photochemical Activation of Aromatic Aldehydes: Synthesis of Amides, Hydroxamic Acids and Esters
Nikitas, N. F., Apostolopoulou, M. K., Skolia, E., Tsoukaki, A., & Kokotos, C. G. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202100655 · Cited by 50
Histone crotonylation regulates neural stem cell fate decisions by activating bivalent promoters
Dai, S., Liu, P., Du, H., Liu, X., Xu, Y., Liu, C., Wang, Y.-Y., Teng, Z., & Liu, C. (2021) · EMBO Reports · doi:10.15252/embr.202052023 · Cited by 51
“As a transcription activating modification, histone Kac plays an important role in neurodevelopment and neurological diseases (Falkenberg & Johnstone, 2014; Tang et al , 2019).”
Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents
Wang, C., Zhang, Y., Shi, L., Yang, S., Chang, J., Zhong, Y., Li, Q., & Xing, D. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2074414 · Cited by 53
Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase Enzymes
Maolanon, A. R., Kristensen, H. M. E., Leman, L. J., Ghadiri, M. R., & Olsen, C. A. (2016) · ChemBioChem · doi:10.1002/cbic.201600519 · Cited by 51
Meier, J. C., Tallant, C., Fedorov, O., Witwicka, H., Hwang, S., van Stiphout, R. G. P. M., Lambert, J., Rogers, C. M., Yapp, C., Gerstenberger, B. S., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00481 · Cited by 51
Liao, Y., Xu, L., Ou, S., Edwards, H. J., Luedtke, D. A., Ge, Y., & Qin, Z. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00057 · Cited by 53
Metadata
- Authors
- Falkenberg, K. J., & Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- The University of Melbourne (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-08-18
- Volume
- 13
- Issue
- 9
- Pages
- 673-691
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2046345187
- Cited by
- 1,564
- References
- 281
- Citations by year
- 2026: 82 · 2025: 110 · 2024: 89 · 2023: 96 · 2022: 121 · 2021: 133 · 2020: 160 · 2019: 146 · 2018: 134 · 2017: 166 · 2016: 208 · 2015: 108 · 2014: 8
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Update notices
- addendum (2015-02-27)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase, histone deacetylase inhibitors, epigenetic regulation, cancer, neurological disorders, immune disorders, small molecule inhibitors, lysine deacetylation, epigenetic aberrations, drug development
- MeSH terms
- Animals, Histone Deacetylases, Humans, Immune System Diseases, Neoplasms, Nervous System Diseases, Epigenesis, Genetic, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.